| Q39894314 | A Practical Guide to The Cancer Genome Atlas (TCGA). |
| Q104607073 | A Prognostic Molecular Signature of N⁶-Methyladenosine Methylation Regulators for Soft-Tissue Sarcoma from The Cancer Genome Atlas Database |
| Q91693561 | A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset |
| Q33869005 | A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data |
| Q92030290 | A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression |
| Q33944976 | A pan-cancer proteomic perspective on The Cancer Genome Atlas. |
| Q96025679 | A potential prognostic model based on miRNA expression profile in The Cancer Genome Atlas for bladder cancer patients |
| Q33453324 | A primer on a hepatocellular carcinoma bioresource bank using the cancer genome atlas guidelines: practical issues and pitfalls |
| Q47817583 | A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. |
| Q28703616 | A self-updating road map of The Cancer Genome Atlas |
| Q37227494 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas |
| Q100401756 | AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas |
| Q92683353 | Accuracy of The Cancer Genome Atlas Classification vs American Joint Committee on Cancer Classification for Prediction of Metastasis in Patients With Uveal Melanoma |
| Q47096364 | Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features |
| Q30982552 | Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results |
| Q33566622 | Analysis of The Cancer Genome Atlas sequencing data reveals novel properties of the human papillomavirus 16 genome in head and neck squamous cell carcinoma |
| Q42367899 | Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancer |
| Q56888014 | Analysis of key genes and signaling pathways involved in Helicobacter pylori-associated gastric cancer based on The Cancer Genome Atlas database and RNA sequencing data |
| Q36328507 | Analysis of single nucleotide variants of HFE gene and association to survival in The Cancer Genome Atlas GBM data |
| Q90479569 | Analysis of the Cancer Genome Atlas Data Reveals Novel Putative ncRNAs Targets in Hepatocellular Carcinoma |
| Q101044501 | Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database |
| Q96692456 | Analysis of the Role and Regulatory Mechanism of hsa-miR-504 in Cervical Cancer Based on The Cancer Genome Atlas Database |
| Q47425171 | Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. |
| Q91677755 | Analysis of the cancer genome atlas data to determine the correlation between PROX1 and TERT in hepatocellular carcinoma |
| Q36874944 | Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer |
| Q39691526 | Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project. |
| Q40045129 | Associations of two-pore domain potassium channels and triple negative breast cancer subtype in The Cancer Genome Atlas: systematic evaluation of gene expression and methylation |
| Q87245388 | BAP1 is overexpressed in black compared with white patients with Mx-M1 clear cell renal cell carcinoma: A report from the cancer genome atlas |
| Q38682221 | BCL2 Regulation According to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database |
| Q92646012 | Banding Together: A Systematic Comparison of The Cancer Genome Atlas and the Mitelman Databases |
| Q40299373 | Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics |
| Q33828083 | Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data |
| Q100961820 | CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study |
| Q91069420 | Characteristics of The Cancer Genome Atlas cases relative to U.S. general population cancer cases |
| Q104284888 | Characterization of TERT and BRAF Copy Number Variation in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas (TCGA) Study |
| Q64933166 | Characterization of bidirectional gene pairs in The Cancer Genome Atlas (TCGA) dataset. |
| Q64089532 | Characterization of mRNA Expression and Endogenous RNA Profiles in Bladder Cancer Based on The Cancer Genome Atlas (TCGA) Database |
| Q37410593 | Characterizing DNA methylation alterations from The Cancer Genome Atlas |
| Q49948875 | Chromaffin cell biology: inferences from The Cancer Genome Atlas |
| Q51434967 | Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database |
| Q38647480 | Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA). |
| Q38659483 | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. |
| Q88399437 | Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR |
| Q38433308 | Clinical Value and Prospective Pathway Signaling of MicroRNA-375 in Lung Adenocarcinoma: A Study Based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Bioinformatics Analysis |
| Q33602610 | Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics. |
| Q44640522 | Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma |
| Q38794742 | Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases |
| Q64240657 | Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer |
| Q92609690 | Clinical value screening, prognostic significance and key pathway identification of miR-204-5p in endometrial carcinoma: A study based on the Cancer Genome Atlas (TCGA), and bioinformatics analysis |
| Q96762410 | Coexpression Analysis of the EZH2 Gene Using The Cancer Genome Atlas and Oncomine Databases Identifies Coexpressed Genes Involved in Biological Networks in Breast Cancer, Glioblastoma, and Prostate Cancer |
| Q35930811 | Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. |
| Q38804228 | Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas |
| Q90690161 | Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort |
| Q102220189 | Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases |
| Q96350756 | Comprehensive Analysis of Competing Endogenous RNA (ceRNA) Network Based on RNAs Differentially Expressed in Lung Adenocarcinoma Using The Cancer Genome Atlas (TCGA) Database |
| Q38901483 | Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. |
| Q34357859 | Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples |
| Q30868379 | Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data |
| Q42551460 | Correction: Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas |
| Q42662344 | Correction: intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas |
| Q64245501 | Correlation Patterns Between DNA Methylation and Gene Expression in The Cancer Genome Atlas |
| Q86616218 | Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas |
| Q28392625 | CrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanisms |
| Q56888288 | Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms |
| Q33915083 | DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas |
| Q61804274 | DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas |
| Q28595814 | DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS |
| Q26786399 | Data mining The Cancer Genome Atlas in the era of precision cancer medicine |
| Q39679490 | Defining neoplastic diseases differently: An emerging paradigm from The Cancer Genome Atlas lower-grade gliomas project |
| Q90480562 | Deregulation of cell adhesion molecules is associated with progression and poor outcomes in endometrial cancer: Analysis of The Cancer Genome Atlas data |
| Q101145823 | Determining the Clinical Value and Critical Pathway of GTPBP4 in Lung Adenocarcinoma Using a Bioinformatics Strategy: A Study Based on Datasets from The Cancer Genome Atlas |
| Q92827620 | Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas |
| Q61812749 | Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer |
| Q47113981 | Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas |
| Q36327564 | Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas |
| Q90321369 | Differential expression analysis of clear cell renal cell carcinomas in THE CANCER GENOME ATLAS distinguishes an aggressive subset enriched with chromosome 7 and 12 gains |
| Q64236132 | Discovering Cancer Subtypes via an Accurate Fusion Strategy on Multiple Profile Data |
| Q49220207 | Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile. |
| Q42378454 | Dysregulated expression of homeobox family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from The Cancer Genome Atlas. |
| Q90087613 | Dysregulation of the miRNA biogenesis components DICER1, DROSHA, DGCR8 and AGO2 in clear cell renal cell carcinoma in both a Korean cohort and the cancer genome atlas kidney clear cell carcinoma cohort |
| Q83500507 | Effects of hub genes on the clinicopathological and prognostic features of lung adenocarcinoma |
| Q36340870 | Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer |
| Q24595911 | Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas |
| Q36325754 | Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets |
| Q38662152 | Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas |
| Q41577022 | Evaluation of melanoma antigen (MAGE) gene expression in human cancers using The Cancer Genome Atlas. |
| Q64064465 | Evaluation of the prognostic significances of γ-secretase genes in pancreatic cancer |
| Q57646224 | Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas |
| Q98458821 | Exploration of DNA Methylation-Driven Genes in Papillary Thyroid Carcinoma Based on the Cancer Genome Atlas |
| Q31121923 | Exploring cancer genomic data from the cancer genome atlas project |
| Q90609870 | Exploring drivers of gene expression in the Cancer Genome Atlas |
| Q64998069 | Exploring the survival prognosis of lung adenocarcinoma based on the cancer genome atlas database using artificial neural network. |
| Q28741373 | Exposing the cancer genome atlas as a SPARQL endpoint |
| Q64104860 | Expression and clinical value of CD105 in renal cell carcinoma based on data mining in The Cancer Genome Atlas |
| Q64098049 | Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival |
| Q30487456 | Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses |
| Q54090150 | Expression of the Long Intergenic Non-Protein Coding RNA 665 (LINC00665) Gene and the Cell Cycle in Hepatocellular Carcinoma Using The Cancer Genome Atlas, the Gene Expression Omnibus, and Quantitative Real-Time Polymerase Chain Reaction |
| Q30873353 | Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis. |
| Q31066455 | Expression profile analysis of head and neck squamous cell carcinomas using data from The Cancer Genome Atlas |
| Q36015168 | Expression profiles of pivotal microRNAs and targets in thyroid papillary carcinoma: an analysis of The Cancer Genome Atlas |
| Q98565113 | FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry |
| Q41900602 | Feature selection and survival modeling in The Cancer Genome Atlas |
| Q38633856 | Follicular cell thyroid neoplasia: insights from genomics and The Cancer Genome Atlas research network |
| Q60046255 | Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set |
| Q38862963 | Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset |
| Q91544098 | Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D |
| Q42099691 | Genetic profile and biological implication of PIN2/TRF1-interacting telomerase inhibitor 1 (PinX1) in human cancers: an analysis using The Cancer Genome Atlas |
| Q85938023 | Genetics: The Cancer Genome Atlas maps papillary thyroid cancer |
| Q33598001 | Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer |
| Q52607320 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas |
| Q94552635 | Glutathione Peroxidase 8 as a Prognostic Biomarker of Gastric Cancer: An Analysis of The Cancer Genome Atlas (TCGA) Data |
| Q92851393 | Glycolysis-Based Genes Associated with the Clinical Outcome of Pancreatic Ductal Adenocarcinoma Identified by The Cancer Genome Atlas Data Analysis |
| Q38915517 | HeLa nucleic acid contamination in the cancer genome atlas leads to the misidentification of human papillomavirus 18. |
| Q97428132 | High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets |
| Q64122880 | High expression of TRIM36 is associated with radiosensitivity in gastric cancer |
| Q64055840 | Identification of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas |
| Q42314430 | Identification of Histological Correlates of Overall Survival in Lower Grade Gliomas Using a Bag-of-words Paradigm: A Preliminary Analysis Based on Hematoxylin & Eosin Stained Slides from the Lower Grade Glioma Cohort of The Cancer Genome Atlas |
| Q92123414 | Identification of Long Non-Coding RNA Expression Profiles and Co-Expression Genes in Thyroid Carcinoma Based on The Cancer Genome Atlas (TCGA) Database |
| Q98619129 | Identification of MicroRNA-Related Tumorigenesis Variants and Genes in the Cancer Genome Atlas (TCGA) Data |
| Q36222283 | Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas |
| Q96434985 | Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas |
| Q35143770 | Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the Cancer Genome Atlas |
| Q90480579 | Identification of candidate RNA signatures in triple-negative breast cancer by the construction of a competing endogenous RNA network with integrative analyses of Gene Expression Omnibus and The Cancer Genome Atlas data |
| Q60049436 | Identification of differentially expressed miRNAs in early-stage cervical cancer with lymph node metastasis across The Cancer Genome Atlas datasets |
| Q90577178 | Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases |
| Q49438443 | Identification of key miRNAs and genes associated with stomach adenocarcinoma from The Cancer Genome Atlas database |
| Q96344635 | Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas |
| Q93143116 | Identification of microRNAs as novel biomarkers for esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas (TCGA) and bioinformatics |
| Q36348881 | Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: a study of 187 cases |
| Q90402521 | Identification of prognostic miRNA biomarkers for predicting overall survival of colon adenocarcinoma and bioinformatics analysis: A study based on The Cancer Genome Atlas database |
| Q64889734 | Identifying the Antiproliferative Effect of Astragalus Polysaccharides on Breast Cancer: Coupling Network Pharmacology With Targetable Screening From the Cancer Genome Atlas. |
| Q91397791 | Imaging-Genomic Study of Head and Neck Squamous Cell Carcinoma: Associations Between Radiomic Phenotypes and Genomic Mechanisms via Integration of The Cancer Genome Atlas and The Cancer Imaging Archive |
| Q90484486 | Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database |
| Q37435455 | Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas |
| Q98781924 | Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data |
| Q96609190 | Increased Expression of T-Box Transcription Factor Protein 21 (TBX21) in Skin Cutaneous Melanoma Predicts Better Prognosis: A Study Based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) Databases |
| Q37114357 | Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas |
| Q52718288 | Insights into the etiology-associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas |
| Q90061052 | Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas |
| Q92314726 | Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas |
| Q90603137 | Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas |
| Q57174326 | Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas |
| Q91233616 | Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data |
| Q36883783 | Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival |
| Q95261215 | Integrative analysis of ceRNA network and DNA methylation associated with gene expression in malignant pheochromocytomas: a study based on The Cancer Genome Atlas |
| Q58711412 | Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas |
| Q102333881 | Interferon-lambda (IFNL) germline variations and their significance for HCC and PDAC progression: an analysis of The Cancer Genome Atlas (TCGA) data |
| Q51196841 | Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. |
| Q28650140 | Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas |
| Q30491122 | Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer? |
| Q92167623 | Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients |
| Q92488691 | KRAB ZNF explorer-the online tool for the exploration of the transcriptomic profiles of KRAB-ZNF factors in The Cancer Genome Atlas |
| Q40009522 | L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). |
| Q52715015 | LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data |
| Q35786761 | Landscape of expression profiles in esophageal carcinoma by The Cancer Genome Atlas data |
| Q35745473 | Large-scale profiling of microRNAs for The Cancer Genome Atlas. |
| Q55459820 | Letter to the Editor: Misuse of The Cancer Genome Atlas? |
| Q93092197 | Lymph node metastasis in lung squamous cell carcinoma and identification of metastasis-related genes based on the Cancer Genome Atlas |
| Q47156578 | MINTbase v2.0: a comprehensive database for tRNA-derived fragments that includes nuclear and mitochondrial fragments from all The Cancer Genome Atlas projects |
| Q52607333 | Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas |
| Q90832318 | Massive computational identification of somatic variants in exonic splicing enhancers using The Cancer Genome Atlas |
| Q96017864 | Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas |
| Q64083911 | Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles |
| Q92243276 | MiR-195 restrains lung adenocarcinoma by regulating CD4+ T cell activation via the CCDC88C/Wnt signaling pathway: a study based on the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and bioinformatic analysis |
| Q41709514 | MicroRNA signatures predict prognosis of patients with glioblastoma multiforme through the Cancer Genome Atlas |
| Q47751663 | MicroRNA-128 expression not associated with glioma-associated epilepsy in WHO grades 2 glioma: Data from the Cancer Genome Atlas (TCGA) project |
| Q43705906 | MicroRNA-21 expression in the prognosis of low-grade gliomas: data from the cancer genome atlas (TCGA) project. |
| Q96295170 | Microarray expression profile of microRNAs in lung adenocarcinoma patients with the Cancer Genome Atlas and its clinical validation |
| Q36416465 | Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study |
| Q92257868 | Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project |
| Q47702153 | Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data |
| Q34778891 | Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project |
| Q38392332 | Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network |
| Q58608059 | Molecular correlates of metastasis by systematic pan-cancer analysis across The Cancer Genome Atlas |
| Q38782130 | Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications |
| Q99630168 | Multi-omics integrative analysis and survival risk model construction of non-small cell lung cancer based on The Cancer Genome Atlas datasets |
| Q35707516 | Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival |
| Q100750034 | Multiomics integrative analysis for gene signatures and prognostic values of m6A regulators in pancreatic adenocarcinoma: a retrospective study in The Cancer Genome Atlas project |
| Q33600399 | Mutations of Chromatin Structure Regulating Genes in Human Malignancies |
| Q64055892 | NGFI-A Binding Protein 2 Promotes EGF-Dependent HNSCC Cell Invasion |
| Q90454845 | Network Rewiring in Cancer: Applications to Melanoma Cell Lines and the Cancer Genome Atlas Patients |
| Q97885854 | Network-Based Approach to Identify the Antiproliferative Mechanisms of Bruceine D in Breast Cancer From the Cancer Genome Atlas |
| Q58194989 | New molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas |
| Q58194992 | New molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas |
| Q36138030 | Next Generation Sequencing: The Next Iteration of Personalized Medicine: Next generation sequencing, along with expanding databases like The Cancer Genome Atlas, has the potential to aid rational drug discovery and streamline clinical trials. |
| Q54966119 | OS09.1 Radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with lower grade glioma in the Cancer Genome Atlas (TCGA) Dataset. |
| Q64099550 | Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource |
| Q58584826 | Onco-Multi-OMICS Approach: A New Frontier in Cancer Research |
| Q52602404 | Oncogenic Signaling Pathways in The Cancer Genome Atlas |
| Q41198310 | Overlap of the cancer genome atlas and the immune epitope database |
| Q57810287 | PR/SET Domain Family and Cancer: Novel Insights from the Cancer Genome Atlas |
| Q52723228 | Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas |
| Q55497366 | Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). |
| Q93034368 | Pan-cancer analysis of iron metabolic landscape across the Cancer Genome Atlas |
| Q60044760 | Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas |
| Q47210442 | Pan-cancer insights from The Cancer Genome Atlas: the pathologist's perspective |
| Q50462732 | Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas |
| Q99551753 | Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database |
| Q64115497 | Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA |
| Q35666752 | Possible Human Papillomavirus 38 Contamination of Endometrial Cancer RNA Sequencing Samples in The Cancer Genome Atlas Database |
| Q92996654 | Potential prognostic impact of EBV RNA-seq reads in gastric cancer: a reanalysis of The Cancer Genome Atlas cohort |
| Q38424919 | Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. |
| Q58135337 | Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas |
| Q61804788 | Predicting drug response of tumors from integrated genomic profiles by deep neural networks |
| Q42668955 | Presence of viral DNA in whole-genome sequencing of brain tumor tissues from the cancer genome atlas |
| Q45907253 | Previously defined 53 immune gene panel predicts melanoma survival using The Cancer Genome Atlas (TCGA). |
| Q91858303 | Prognostic Importance of Age, Tumor Location, and Tumor Grade in Grade II Astrocytomas: An Integrated Analysis of the Cancer Genome Atlas and the Surveillance, Epidemiology, and End Results Database |
| Q90984788 | Prognostic implications of aberrantly expressed methylation‑driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas |
| Q37094944 | Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas |
| Q47427120 | Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: A study based on The Cancer Genome Atlas and bioinformatics investigation |
| Q91673510 | Prognostic value of aberrantly expressed methylation gene profiles in lung squamous cell carcinoma: A study based on The Cancer Genome Atlas |
| Q52648133 | Prognostic value of estrogen receptor α and estrogen receptor β in gastric cancer based on a meta-analysis and The Cancer Genome Atlas (TCGA) datasets |
| Q91392247 | Prognostication of uveal melanoma is simple and highly predictive using The Cancer Genome Atlas (TCGA) classification: A review |
| Q86839274 | Proteomics of Colorectal Cancer in a Genomic Context: First Large-scale Mass Spectrometry-Based Analysis from the Cancer Genome Atlas |
| Q48420785 | Q&A: Anna Barker on The Cancer Genome Atlas |
| Q36483446 | REPURPOSING GERMLINE EXOMES OF THE CANCER GENOME ATLAS DEMANDS A CAUTIOUS APPROACH AND SAMPLE-SPECIFIC VARIANT FILTERING |
| Q37703453 | Racial Differences in Expression Levels of miRNA Machinery-Related Genes, Dicer, Drosha, DGCR8, and AGO2, in Asian Korean Papillary Thyroid Carcinoma and Comparative Validation Using the Cancer Genome Atlas |
| Q55008423 | Racial differences in endometrial cancer molecular portraits in The Cancer Genome Atlas. |
| Q36412660 | Radiogenomics of High-Grade Serous Ovarian Cancer: Multireader Multi-Institutional Study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group |
| Q35574106 | Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group |
| Q38805727 | Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. |
| Q50055393 | Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65. |
| Q91085378 | Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas |
| Q31166162 | Recurrence-associated genes in papillary thyroid cancer: An analysis of data from The Cancer Genome Atlas |
| Q38611444 | Regulation of Pharmacogene Expression by microRNA in The Cancer Genome Atlas (TCGA) Research Network |
| Q38668393 | Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database |
| Q96306244 | Reveal the Regulation Patterns of Prognosis-Related miRNAs and lncRNAs Across Solid Tumors in the Cancer Genome Atlas |
| Q104496126 | Screening and Identification of Prognostic Tumor-Infiltrating Immune Cells and Genes of Endometrioid Endometrial Adenocarcinoma: Based on The Cancer Genome Atlas Database and Bioinformatics |
| Q89622465 | Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia |
| Q64096457 | Short hairpin RNA-mediated knockdown of nuclear factor erythroid 2-like 3 exhibits tumor-suppressing effects in hepatocellular carcinoma cells |
| Q31114420 | Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data |
| Q40650418 | Smoking correlates with increased cytoskeletal protein-related coding region mutations in the lung and head and neck datasets of the cancer genome atlas |
| Q31140460 | Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project |
| Q42589302 | Superhighway or blind alley? The cancer genome atlas releases first results. |
| Q94587114 | Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data |
| Q92028316 | Systematic analysis and prediction model construction of alternative splicing events in hepatocellular carcinoma: a study on the basis of large-scale spliceseq data from The Cancer Genome Atlas |
| Q64067342 | Systematic characterization of germline variants from the DiscovEHR study endometrial carcinoma population |
| Q92993050 | Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts |
| Q90347849 | Systematical Analysis of the Cancer Genome Atlas Database Reveals EMCN/MUC15 Combination as a Prognostic Signature for Gastric Cancer |
| Q36238734 | TCGA2BED: extracting, extending, integrating, and querying The Cancer Genome Atlas |
| Q37636824 | TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas |
| Q90443964 | TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database |
| Q57824189 | TRGAted: A web tool for survival analysis using protein data in the Cancer Genome Atlas |
| Q92608385 | The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network |
| Q97417582 | The Cancer Genome Atlas (TCGA) based m6A methylation-related genes predict prognosis in hepatocellular carcinoma |
| Q35066321 | The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge |
| Q36756817 | The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma. |
| Q36220226 | The Cancer Genome Atlas Clinical Explorer: a web and mobile interface for identifying clinical-genomic driver associations |
| Q52607313 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma |
| Q57261171 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma |
| Q92244263 | The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability |
| Q24606808 | The Cancer Genome Atlas Pan-Cancer analysis project |
| Q91244741 | The Cancer Genome Atlas Project in Bladder Cancer |
| Q95785557 | The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer |
| Q90390615 | The Cancer Genome Atlas Project: An Integrated Molecular View of Uveal Melanoma |
| Q92356174 | The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells |
| Q38210549 | The Cancer Genome Atlas expression profiles of low-grade gliomas |
| Q47601467 | The Cancer Genome Atlas findings in head and neck cancer: a renewed hope. |
| Q91666595 | The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications |
| Q88292777 | The Cancer Genome Atlas: Creating Lasting Value beyond Its Data |
| Q38195619 | The Cancer Genome Atlas: clinical applications for breast cancer |
| Q38655038 | The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas |
| Q52615642 | The Pancancer DNA Methylation Trackhub: A Window to The Cancer Genome Atlas Epigenomics Data |
| Q91571856 | The Role of Significantly Deregulated MicroRNAs in Recurrent Cervical Cancer Based on Bioinformatic Analysis of the Cancer Genome Atlas Data |
| Q85904268 | The cancer genome atlas research network: a sight to behold |
| Q36606199 | The cancer genome atlas: new weapon in old war? |
| Q90780438 | The clinical applications of The Cancer Genome Atlas project for bladder cancer |
| Q64227635 | The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma: A meta-analysis validated by the Cancer Genome Atlas dataset |
| Q60301577 | The construction and analysis of ceRNA networks in invasive breast cancer: a study based on The Cancer Genome Atlas |
| Q95261185 | The construction and analysis of competitive endogenous RNA (ceRNA) networks in metastatic renal cell carcinoma: a study based on The Cancer Genome Atlas |
| Q55311780 | The expression of HOXA13 in lung adenocarcinoma and its clinical significance: A study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction. |
| Q28084190 | The impact of the Cancer Genome Atlas on lung cancer. |
| Q92495512 | The prognostic value of long non-coding RNA H19 in various cancers: A meta-analysis based on 15 studies with 1584 patients and the Cancer Genome Atlas data |
| Q64228733 | Three Poliovirus Sequences in the Human Genome Associated With Colorectal Cancer |
| Q64265490 | Transcriptional regulation of Bcl-2 gene by the PR/SET domain family member PRDM10 |
| Q90821014 | Uncovering the potential differentially expressed miRNAs as diagnostic biomarkers for hepatocellular carcinoma based on machine learning in The Cancer Genome Atlas database |
| Q91462847 | Unraveling 'The Cancer Genome Atlas' information on the role of SLC transporters in anticancer drug uptake |
| Q36150692 | Update on The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer |
| Q31142278 | Upregulation of SLC2 (GLUT) family genes is related to poor survival outcomes in papillary thyroid carcinoma: Analysis of data from The Cancer Genome Atlas. |
| Q90868678 | Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses |
| Q104736164 | Using The Cancer Genome Atlas as an Inquiry Tool in the Undergraduate Classroom |
| Q99354725 | Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma |
| Q103793897 | Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups |
| Q36399985 | Validation and calibration of next-generation sequencing to identify Epstein-Barr virus-positive gastric cancer in The Cancer Genome Atlas |
| Q37636947 | Weighted gene co-expression network analysis in identification of metastasis-related genes of lung squamous cell carcinoma based on the Cancer Genome Atlas database |
| Q92658129 | What "The Cancer Genome Atlas" database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs |
| Q92063656 | [A new bioinformatics approach for prediction of potential tumor neoantigens based on the cancer genome atlas dataset] |
| Q57753610 | [Data mining of esophageal squamous cell carcinoma from The Cancer Genome Atlas database] |
| Q89441860 | mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas |
| Q64069245 | von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53 |